Akumentis Healthcare Unveils Drug For Treatment of Epilepsy

India Pharma Outlook Team | Thursday, 11 January 2024

 India Pharma Outlook Team

Akumentis Healthcare Limited has launched Clasepi to combat epilepsy-related issues. Clasepi, a DCGI-approved prescription cannabidiol (CBD), is specifically developed to treat seizures caused by Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC) in patients aged one year and up.

Clasepi marks a development as the first synthetic CBD product of its kind to be made available in India. The product with THC content below 0.1 per cent, stands out for its non-psychotropic nature. Clinical studies have demonstrated Clasepi's efficacy in reducing seizures, especially in cases where conventional antiseizure medications have proven ineffective, as per economic times.

Kanishk Jain, Executive Director, Akumentis, said, “Patients grappling with a rare and severe form of epilepsy often endure a protracted journey to obtain an accurate diagnosis, tolerating nearly five years of uncontrolled seizures from the onset. In certain instances, individuals may enter adulthood without a precise diagnosis, despite wrestling with conditions like Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, or Tuberous Sclerosis Complex (TSC).”

Pradeep Patni, Chief Executive Officer, Akumentis, added, “Clasepi is carefully designed to meet the specific needs of conditions, recognising the limitations of traditional anti-epilepsy medicines.”

Clasepi should not be used if you are allergic to cannabidiol or any of its constituents. Akumentis emphasizes the need of following healthcare experts prescription guidelines for optimal use and safe consumption

© 2024 India Pharma Outlook. All Rights Reserved.